ARCH THERAPEUTICS, INC.: 10-Q filed 2024-02-20

Name: ARCH THERAPEUTICS, INC.: 10-Q filed 2024-02-20
Creator: ARCH THERAPEUTICS, INC.

What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2024-02-20 (fiscal Q1 2024): 25 published measures, 52 facts as tagged in accession 0001437749-24-004857.

This filing

Form: 10-Q (quarterly report)
Filed: 2024-02-20
Fiscal period: fiscal Q1 2024
Accession: 0001437749-24-004857 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-12-31	1,821,947	USD
At 2023-09-30	1,958,189	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-12-31	-9,575,516	USD
At 2023-09-30	-7,507,732	USD
At 2022-12-31	-5,888,836	USD
At 2022-09-30	-4,192,806	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	-2,681,652	USD	92
2022-10-01 to 2022-12-31	-1,800,056	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	-862,605	USD	92
2022-10-01 to 2022-12-31	-650,065	USD	92

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	45,867	USD	92
2022-10-01 to 2022-12-31	6,261	USD	92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	845,735	USD	92
2022-10-01 to 2022-12-31	-86,257	USD	92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-12-31	-64,737,261	USD
At 2023-09-30	-62,055,609	USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	-0.57	USD/shares	92
2022-10-01 to 2022-12-31	-1.44	USD/shares	92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-12-31	3,949	USD
At 2023-09-30	4,599	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	25,909	USD	92
2022-10-01 to 2022-12-31	104,026	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	-1,494,669	USD	92
2022-10-01 to 2022-12-31	-1,275,743	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-12-31	1,814,498	USD
At 2023-09-30	1,950,090	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	1,186,983	USD	92
2022-10-01 to 2022-12-31	524,313	USD	92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-12-31	11,397,463	USD
At 2023-09-30	9,465,921	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-12-31	2,772,424	USD
At 2023-09-30	2,304,207	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2023-12-31	1,335,849	USD
At 2023-09-30	1,364,504	USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	23,606	USD	92
2022-10-01 to 2022-12-31	17,635	USD	92

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	1,311,350	USD	92
2022-10-01 to 2022-12-31	1,102,916	USD	92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	205,580	USD	92
2022-10-01 to 2022-12-31	161,453	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-12-31	4,742,364	shares
At 2023-09-30	4,689,446	shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-12-31	3,500	USD
At 2023-09-30	3,500	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-12-31	272,799	USD
At 2023-09-30	362,866	USD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	650	USD	92
2022-10-01 to 2022-12-31	663	USD	92

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	-28,655	USD	92
2022-10-01 to 2022-12-31	-3,211	USD	92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-10-01 to 2023-12-31	468,217	USD	92
2022-10-01 to 2022-12-31	433,482	USD	92

Inspect the source

Entity: ARCH THERAPEUTICS, INC. / CIK 0001537561
Captured: 2026-09-22 19:51 UTC
SEC response SHA-256: 63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))